Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countriesnews2024-10-02T23:12:20+00:00October 2nd, 2024|The New York Times|
Gilead Shot Provides Total Protection From HIV in Trial of Young African Womennews2024-06-21T23:30:20+00:00June 21st, 2024|The New York Times|
Los fármacos de acción prolongada podrían revolucionar el tratamiento de VIHnews2024-04-21T07:02:00+00:00April 21st, 2024|The New York Times|
Long-Acting Drugs May Revolutionize H.I.V. Prevention and Treatmentnews2024-04-17T22:46:45+00:00April 17th, 2024|The New York Times|
10 Charged in $20 Million Scheme to Sell Black-Market H.I.V. Drugsnews2023-10-21T02:05:57+00:00October 21st, 2023|The New York Times|
PEPFAR Turned the Tide of AIDS and It’s Now at Risknews2023-09-21T19:59:01+00:00September 21st, 2023|The New York Times|
Why One Drug Company Held Back a Better Drugnews2023-09-07T10:00:12+00:00September 7th, 2023|The New York Times|
Expert Panel Recommends New Drugs for HIV Preventionnews2023-08-22T15:55:45+00:00August 22nd, 2023|The New York Times|
How Gilead Profited by Slow-Walking a Promising H.I.V. Therapynews2023-07-22T18:26:55+00:00July 22nd, 2023|The New York Times|
When Politics Saves Lives: a Good-News Storynews2023-06-07T17:50:17+00:00June 7th, 2023|The New York Times|
